Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

CollPlant Biotechnologies (CLGN) Interest & Investment Income (2017 - 2021)

Historic Interest & Investment Income for CollPlant Biotechnologies (CLGN) over the last 5 years, with Q4 2021 value amounting to -$188.8 million.

  • CollPlant Biotechnologies' Interest & Investment Income fell 101309.55% to -$188.8 million in Q4 2021 from the same period last year, while for Dec 2021 it was -$121.7 million, marking a year-over-year decrease of 30424750.0%. This contributed to the annual value of $738000.0 for FY2024, which is 634.52% down from last year.
  • According to the latest figures from Q4 2021, CollPlant Biotechnologies' Interest & Investment Income is -$188.8 million, which was down 101309.55% from $67.0 million recorded in Q3 2021.
  • In the past 5 years, CollPlant Biotechnologies' Interest & Investment Income registered a high of $67.0 million during Q3 2021, and its lowest value of -$188.8 million during Q4 2021.
  • In the last 5 years, CollPlant Biotechnologies' Interest & Investment Income had a median value of $9000.0 in 2020 and averaged -$8.1 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first surged by 144042.55% in 2019, then tumbled by 101309.55% in 2021.
  • Over the past 5 years, CollPlant Biotechnologies' Interest & Investment Income (Quarter) stood at -$81000.0 in 2017, then skyrocketed by 666.67% to $459000.0 in 2018, then surged by 37.25% to $630000.0 in 2019, then crashed by 2792.06% to -$17.0 million in 2020, then crashed by 1013.1% to -$188.8 million in 2021.
  • Its Interest & Investment Income stands at -$188.8 million for Q4 2021, versus $67.0 million for Q3 2021 and $72000.0 for Q2 2021.